These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9972133)
21. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106 [TBL] [Abstract][Full Text] [Related]
22. Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Hurewitz AN; Wu CL; Mancuso P; Zucker S Chest; 1993 Apr; 103(4):1113-7. PubMed ID: 8131449 [TBL] [Abstract][Full Text] [Related]
23. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Duivenvoorden WC; Hirte HW; Singh G Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290 [TBL] [Abstract][Full Text] [Related]
24. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901 [TBL] [Abstract][Full Text] [Related]
25. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Porter KE; Thompson MM; Loftus IM; McDermott E; Jones L; Crowther M; Bell PR; London NJ Eur J Vasc Endovasc Surg; 1999 May; 17(5):404-12. PubMed ID: 10329524 [TBL] [Abstract][Full Text] [Related]
26. Wound healing in aged normal and ovariectomized rats: effects of chemically modified doxycycline (CMT-8) on MMP expression and collagen synthesis. Ramamurthy NS; McClain SA; Pirila E; Maisi P; Salo T; Kucine A; Sorsa T; Vishram F; Golub LM Ann N Y Acad Sci; 1999 Jun; 878():720-3. PubMed ID: 10415818 [No Abstract] [Full Text] [Related]
30. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review. Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Gu Y; Lee HM; Golub LM; Sorsa T; Konttinen YT; Simon SR Ann Med; 2005; 37(6):450-60. PubMed ID: 16203617 [TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells. Bildt MM; Bloemen M; Kuijpers-Jagtman AM; Von den Hoff JW J Periodontal Res; 2009 Apr; 44(2):266-74. PubMed ID: 18973523 [TBL] [Abstract][Full Text] [Related]
37. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475 [TBL] [Abstract][Full Text] [Related]
38. Doxycycline-mediated inhibition of corneal angiogenesis: an MMP-independent mechanism. Su W; Li Z; Li F; Chen X; Wan Q; Liang D Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):783-8. PubMed ID: 23249709 [TBL] [Abstract][Full Text] [Related]
39. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Tolomeo M; Grimaudo S; Milano S; La Rosa M; Ferlazzo V; Di Bella G; Barbera C; Simoni D; D'Agostino P; Cillari E Br J Pharmacol; 2001 May; 133(2):306-14. PubMed ID: 11350867 [TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]